You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀下調開拓藥業-B(09939.HK)目標價至72.2元 評級「買入」
阿思達克 11-01 11:29
瑞銀發表研究報告指,默沙東藥廠近日公布旗下口服候選藥物莫努匹韋(molnupiravir)第三期臨床試驗結果,數據表現正面,該產品可用於對抗新冠病毒,連同上月公司提交的緊急使用授權申請,預期莫努匹韋有機會成為全球首款獲批用於治療新冠的口服藥物。 報告指出,莫努匹韋研究進度超越開拓藥業(09939.HK)的同類產品普克魯胺(proxalutamide),預期普克魯胺第三期中期數據可能要到12月才發布,但認為投資者對莫努匹韋的潛在威脅反應過度,或忽視開拓藥業的普克魯胺具有潛在更好療效和安全性,以及更廣泛的患者覆蓋範圍。瑞銀下調普克魯胺的銷售預測,並更新對公司的盈利預測,料2021年每股虧損達1.45元人民幣,2022至2023年每股盈利預測分別下調25%及26%至16.85元人民幣及9.05元人民幣,目標價由92.3元降至72.2元,維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account